Skip to main content
CRNX
NASDAQ Life Sciences

Crinetics' PALSONIFY 获得欧盟批准用于治疗成年人乙状腺功能亢进症，为欧洲推广铺平道路

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$39.74
Mkt Cap
$4.044B
52W Low
$25.83
52W High
$57.99
Market data snapshot near publication time

summarizeSummary

Crinetics Pharmaceuticals 获得了欧洲委员会对 PALSONIFY (paltusotine) 用于成年人乙状腺功能亢进症治疗的批准。这标志着一个重要的里程碑，因为它是该公司在美国以外的第一个监管批准，之前获得了 FDA 批准和美国商业推出，并且在最近的 10-K 中提到了积极的 EU 监管意见。该批准涵盖了所有 27 个欧盟成员国和三个欧洲经济区国家，显著扩大了 PALSONIFY 的总可寻址市场，PALSONIFY 是 Crinetics 的一个关键产品。计划在德国和奥地利进行初步商业化努力。预计这一积极的发展将成为未来收入增长的重要驱动力，并巩固了 PALSONIFY 作为全球乙状腺功能亢进症领先治疗方法的地位。投资者现在将关注欧洲推出时间表和销售增长的细节。

在该公告发布时，CRNX的交易价格为$39.74，交易所为NASDAQ，所属行业为Life Sciences，市值约为$40.4亿。 52周交易区间为$25.83至$57.99。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CRNX - Latest Insights

CRNX
Apr 27, 2026, 5:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Crinetics' PALSONIFY Wins EU Approval for Acromegaly, Paving Way for European Launch
Sentiment: Positive
View Wiseek Article
CRNX
Mar 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Crinetics Submits Palsonify MAA in Brazil, Expanding Global Reach for Acromegaly Treatment
Sentiment: Positive
View Wiseek Article
CRNX
Mar 23, 2026, 9:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Crinetics Pharmaceuticals CDOO Resigns to Pursue New Opportunity
Sentiment: Neutral
View Wiseek Article
CRNX
Feb 26, 2026, 4:25 PM EST
Filing Type: 10-K
Importance Score:
8
Crinetics Pharmaceuticals Reports First Product Revenue, Positive EU Regulatory Opinion for PALSONIFY, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
CRNX
Feb 26, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Reports First PALSONIFY Product Revenue of $5.4M in Q4 2025, Strong Launch, Positive EU Opinion, and Pipeline Progress
Sentiment: Positive
View Wiseek Article
CRNX
Jan 13, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Reports Early PALSONIFY Revenue, Strong Cash, and Advances Multiple Programs to Phase 3
Sentiment: Positive
View Wiseek Article
CRNX
Jan 07, 2026, 4:39 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Pharmaceuticals Prices $350M Public Offering at Discount to Market, Securing Significant Capital
Sentiment: Neutral
View Wiseek Article
CRNX
Jan 07, 2026, 4:03 PM EST
Filing Type: 424B5
Importance Score:
8
Crinetics Pharmaceuticals Announces $350M Public Offering at Discounted Price
Sentiment: Negative
View Wiseek Article
CRNX
Jan 05, 2026, 4:20 PM EST
Filing Type: 424B5
Importance Score:
8
Crinetics Pharmaceuticals Announces $350M Common Stock Offering to Fund Commercial Launch and R&D
Sentiment: Negative
View Wiseek Article
CRNX
Jan 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Reports Strong PALSONIFY Launch & Positive Phase 2 Atumelnant Data for CAH
Sentiment: Positive
View Wiseek Article